<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166603">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02048098</url>
  </required_header>
  <id_info>
    <org_study_id>atauni9</org_study_id>
    <nct_id>NCT02048098</nct_id>
  </id_info>
  <brief_title>Misoprostol for Second Trimester Termination of Pregnancy</brief_title>
  <official_title>A Comparison Between Vaginal Misoprostol vs. Buccal Misoprostol For Second Trimester Termination of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of 400 µg  vaginal misoprostol  per 3
      hours to 400 µg buccal misoprostol per 3 hours in second trimester termination of viable
      pregnancy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Induction to fetal expulsion interval</measure>
    <time_frame>15 minutes after fetus delivered</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time elapsed between administration of the first misoprostol dose until expulsion of the fetus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delivery within 24 hours</measure>
    <time_frame>24 hour</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery within 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of additional interventions</measure>
    <time_frame>One week</time_frame>
    <safety_issue>No</safety_issue>
    <description>the patients who did not delivered within 48 hours will considered as failed induction and will be offered another method of induction/delivery or to continue same protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived pain before induction and after abortion completed</measure>
    <time_frame>within 1 hour after randomisation and after 12 hour after complete abortion/placenta removed</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perceived pain will be measured by Face Pain Scale-Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete abortion</measure>
    <time_frame>12 hour after fetus and placenta removed</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>total misoprostol dose</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>difference in hematocrit measured at entry of the study  and after delivery/abortion</measure>
    <time_frame>at recruitment and 24 hour after abortion</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>maternal complications</measure>
    <time_frame>one weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>includes, but not limited blood, transfusions, laparatomy, nausea, vomiting, fever, genital tract injury</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>Buccal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 µg buccal misoprostol per 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 µg vaginal misoprostol per 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal misoprostol</intervention_name>
    <description>400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses  will be administered. If abortion  had not occured in 48 hour after the start of the study  it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.</description>
    <arm_group_label>vaginal misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buccal misoprostol</intervention_name>
    <description>400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses  will be administered. If abortion  had not occured in 48 hour after the start of the study  it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.</description>
    <arm_group_label>Buccal misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age between 12-24 weeks

          -  live fetus

          -  singleton pregnancy

          -  Bishop score &lt;5

          -  no uterine contraction

        Exclusion Criteria:

          -  prostaglandin allergy

          -  a scar in uterus

          -  uterine abnormality

          -  premature rupture of membranes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ragıp A AL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ataturk University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ömer E Yapça, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ataturk University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ragıp A Al, MD</last_name>
    <phone>00905324861433</phone>
    <email>atakanal@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ataturk Universitesi Araştırma Hastanesi</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ragıp A Al, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Ragıp Atakan Al</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>Labor, Induced</keyword>
  <keyword>Pregnancy Trimester, Second</keyword>
  <keyword>Abortion, Induced</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
